Advanced search
Publication Cover
Scandinavian Journal of Rheumatology Volume 42, 2013 - Issue 4
Submit an article Journal homepage
1,058
Views
29
CrossRef citations to date
0
Altmetric
Research Article

Retention of tocilizumab and anti-tumour necrosis factor drugs in the treatment of rheumatoid arthritis

Y HishitaniDepartment of Respiratory Medicine, Allergy and Rheumatic Diseases, Graduate School of Medicine, Osaka University, Osaka, Japan
,
A OgataDepartment of Respiratory Medicine, Allergy and Rheumatic Diseases, Graduate School of Medicine, Osaka University, Osaka, Japan;Department of Immunopathology, World Premier International Research Centre (WPI), Immunology Frontier Research Centre, Osaka University, JapanCorrespondence[email protected]
,
Y ShimaDepartment of Respiratory Medicine, Allergy and Rheumatic Diseases, Graduate School of Medicine, Osaka University, Osaka, Japan
,
T HiranoDepartment of Respiratory Medicine, Allergy and Rheumatic Diseases, Graduate School of Medicine, Osaka University, Osaka, Japan
,
K EbinaDepartment of Orthopaedic Surgery, Graduate School of Medicine, Osaka University, Osaka, Japan
,
Y KunugizaDepartment of Orthopaedic Surgery, Graduate School of Medicine, Osaka University, Osaka, Japan
,
K ShiDepartment of Orthopaedic Surgery, Graduate School of Medicine, Osaka University, Osaka, Japan
,
M NarazakiDepartment of Respiratory Medicine, Allergy and Rheumatic Diseases, Graduate School of Medicine, Osaka University, Osaka, Japan
,
K HagiharaDepartment of Kampo Medicine, Graduate School of Medicine, Osaka University, Osaka, Japan
,
T TomitaDepartment of Orthopaedic Surgery, Graduate School of Medicine, Osaka University, Osaka, Japan;Department of Orthopaedic Biomaterial Science, Graduate School of Medicine, Osaka University, Osaka, Japan.
,
H YoshikawaDepartment of Orthopaedic Surgery, Graduate School of Medicine, Osaka University, Osaka, Japan
,
T TanakaDepartment of Immunopathology, World Premier International Research Centre (WPI), Immunology Frontier Research Centre, Osaka University, Japan;Department of Clinical Application of Biologics, Graduate School of Medicine, Osaka University, Osaka, Japan
&
A KumanogohDepartment of Respiratory Medicine, Allergy and Rheumatic Diseases, Graduate School of Medicine, Osaka University, Osaka, Japan;Department of Immunopathology, World Premier International Research Centre (WPI), Immunology Frontier Research Centre, Osaka University, Japan
 show all
Pages 253-259 | Accepted 20 Dec 2012, Published online: 07 Mar 2013

Citations (29)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (7)

Y Nakayama, M Hashimoto, R Watanabe, K Murakami, K Murata, M Tanaka, H Ito, W Yamamoto, K Ebina, K Hata, Y Hiramatsu, M Katayama, Y Son, H Amuro, K Akashi, A Onishi, R Hara, K Yamamoto, K Ohmura, S Matsuda & A Morinobu. (2022) Favorable clinical response and drug retention of anti-IL-6 receptor inhibitor in rheumatoid arthritis with high CRP levels: the ANSWER cohort study. Scandinavian Journal of Rheumatology 51:6, pages 431-440.
Read now
Atsushi Ogata, Yasuhiro Kato, Shinji Higa & Keiji Maeda. (2019) Subcutaneous tocilizumab: recent advances for the treatment of rheumatoid arthritis. Expert Opinion on Drug Delivery 16:6, pages 639-648.
Read now
Atsushi Ogata, Yasuhiro Kato, Shinji Higa & Kazuyuki Yoshizaki. (2019) IL-6 inhibitor for the treatment of rheumatoid arthritis: A comprehensive review. Modern Rheumatology 29:2, pages 258-267.
Read now
Katsuhiko Takabayashi, Fumihiko Ando & Takahiro Suzuki. (2019) Comparing the effectiveness of biological disease-modifying antirheumatic drugs using real-world data. Modern Rheumatology 29:1, pages 87-97.
Read now
Valentin Brodszky, Anikó Bíró, Zoltán Szekanecz, Boglárka Soós, Petra Baji, Fanni Rencz, László Tóthfalusi, László Gulácsi & Márta Péntek. (2017) Determinants of biological drug survival in rheumatoid arthritis: evidence from a Hungarian rheumatology center over 8 years of retrospective data. ClinicoEconomics and Outcomes Research 9, pages 139-147.
Read now
Martin Sheppard, Faidra Laskou, Philip P. Stapleton, Shahryar Hadavi & Bhaskar Dasgupta. (2017) Tocilizumab (Actemra). Human Vaccines & Immunotherapeutics 13:9, pages 1972-1988.
Read now
Toshio Tanaka, Yoshihiro Hishitani & Atsushi Ogata. (2014) Monoclonal antibodies in rheumatoid arthritis: comparative effectiveness of tocilizumab with tumor necrosis factor inhibitors. Biologics: Targets and Therapy 8, pages 141-153.
Read now

Articles from other publishers (22)

Stefka Neycheva, Emilia Naseva, Zguro Batalov, Rositsa Karalilova & Anastas Batalov. (2023) Adherence to biological therapies in patients with rheumatoid arthritis: a retrospective cohort study. Rheumatology International 43:7, pages 1287-1296.
Crossref
Philip J. Mease, Scott Stryker, Mei Liu, Bob Salim, Sabrina Rebello, Mahdi Gharaibeh & David H. Collier. (2021) Treatment patterns in rheumatoid arthritis patients newly initiated on biologic and conventional synthetic disease-modifying antirheumatic drug therapy and enrolled in a North American clinical registry. Arthritis Research & Therapy 23:1.
Crossref
Pascal Hilliquin, Thomas Barnetche, Athan Baillet, René-Marc Flipo, Eric Lespessailles, Christian Roux, Patrice Fardellone, Anika Gilbert-Marceau, Isabelle Idier, Arnaud Constantin, Emilie Shipley, Guy Baudens & Alain Saraux. (2020) Real-World 1-Year Retention Rate of Subcutaneous Tocilizumab Treatment in Patients with Moderate to Severe Active Rheumatoid Arthritis: TANDEM Study. Rheumatology and Therapy 8:1, pages 95-108.
Crossref
Kosuke Ebina, Toru Hirano, Yuichi Maeda, Wataru Yamamoto, Motomu Hashimoto, Koichi Murata, Tohru Takeuchi, Hideyuki Shiba, Yonsu Son, Hideki Amuro, Akira Onishi, Kengo Akashi, Ryota Hara, Masaki Katayama, Keiichi Yamamoto, Atsushi Kumanogoh & Makoto Hirao. (2020) Drug retention of 7 biologics and tofacitinib in biologics-naïve and biologics-switched patients with rheumatoid arthritis: the ANSWER cohort study. Arthritis Research & Therapy 22:1.
Crossref
E. E. Schneeberger, M. A. Acosta Felquer, G. Citera, E. Soriano & E. Mysler. (2020) Long-term persistence of biological agents in the treatment of patients with Rheumatoid Arthritis: a systematic review of the literature. Revista Argentina de Reumatología, pages 6-8.
Crossref
Jennie H. Best, Steven C. Vlad, Lenore Tominna & Ibrahim Abbass. (2020) Real-World Persistence with Tocilizumab Compared to Other Subcutaneous Biologic Disease-Modifying Antirheumatic Drugs Among Patients with Rheumatoid Arthritis Switching from Another Biologic. Rheumatology and Therapy 7:2, pages 345-355.
Crossref
Kosuke Ebina, Motomu Hashimoto, Wataru Yamamoto, Toru Hirano, Ryota Hara, Masaki Katayama, Akira Onishi, Koji Nagai, Yonsu Son, Hideki Amuro, Keiichi Yamamoto, Yuichi Maeda, Koichi Murata, Sadao Jinno, Tohru Takeuchi, Makoto Hirao, Atsushi Kumanogoh & Hideki Yoshikawa. (2019) Drug tolerability and reasons for discontinuation of seven biologics in 4466 treatment courses of rheumatoid arthritis—the ANSWER cohort study. Arthritis Research & Therapy 21:1.
Crossref
Martin Soubrier, Bruno Pereira, Thomas Frayssac, Angelique Fan, Marion Couderc, Sandrine Malochet‐Guinamand, Sylvain Mathieu, Zuzana Tatar, Anne Tournadre & Jean‐Jacques Dubost. (2017) Retention rates of adalimumab, etanercept and infliximab as first‐line biotherapy agent for rheumatoid arthritis patients in daily practice ‐ Auvergne experience. International Journal of Rheumatic Diseases 21:11, pages 1924-1932.
Crossref
Rosarin Sruamsiri, Hideto Kameda & Jörg Mahlich. (2018) Persistence with Biological Disease-modifying Antirheumatic Drugs and Its Associated Resource Utilization and Costs. Drugs - Real World Outcomes 5:3, pages 169-179.
Crossref
Nikos Maniadakis, Emese Toth, Michael Schiff, Xuan Wang, Maria Nassim, Boglarka Szegvari, Irina Mountian & Jeffrey R. Curtis. (2018) A Targeted Literature Review Examining Biologic Therapy Compliance and Persistence in Chronic Inflammatory Diseases to Identify the Associated Unmet Needs, Driving Factors, and Consequences. Advances in Therapy 35:9, pages 1333-1355.
Crossref
Graeme Jones, Stephen Hall, Paul Bird, Geoff Littlejohn, Kathleen Tymms, Peter Youssef, Eric Chung, Rina Barrett & Peter Button. (2017) A retrospective review of the persistence on bDMARD s prescribed for the treatment of rheumatoid arthritis in the Australian population . International Journal of Rheumatic Diseases 21:8, pages 1581-1590.
Crossref
Kosuke Ebina, Motomu Hashimoto, Wataru Yamamoto, Akira Ohnishi, Daijiro Kabata, Toru Hirano, Ryota Hara, Masaki Katayama, Shuzo Yoshida, Koji Nagai, Yonsu Son, Hideki Amuro, Kengo Akashi, Takanori Fujimura, Makoto Hirao, Keiichi Yamamoto, Ayumi Shintani, Atsushi Kumanogoh & Hideki Yoshikawa. (2018) Drug retention and discontinuation reasons between seven biologics in patients with rheumatoid arthritis -The ANSWER cohort study-. PLOS ONE 13:3, pages e0194130.
Crossref
René-Marc Flipo, Jean-Francis Maillefert, Pascal Chazerain, Isabelle Idier, Mathieu Coudert & Jacques Tebib. (2017) Factors influencing the use of tocilizumab as monotherapy in patients with rheumatoid arthritis in a real-life setting: results at 1 year of the ACT-SOLO study. RMD Open 3:1, pages e000340.
Crossref
Anat Fisher, Ken Bassett, Gautam Goel, Dana Stanely, M. Alan Brookhart, Hugh R. Freeman, James M. Wright & Colin R. Dormuth. (2016) Heterogeneity in Comparisons of Discontinuation of Tumor Necrosis Factor Antagonists in Rheumatoid Arthritis - A Meta-Analysis. PLOS ONE 11:12, pages e0168005.
Crossref
Naonobu Sugiyama, Yutaka Kawahito, Takao Fujii, Tatsuya Atsumi, Tatsunori Murata, Yosuke Morishima & Yuri Fukuma. (2016) Treatment Patterns, Direct Cost of Biologics, and Direct Medical Costs for Rheumatoid Arthritis Patients: A Real-world Analysis of Nationwide Japanese Claims Data. Clinical Therapeutics 38:6, pages 1359-1375.e1.
Crossref
Yoshihito Shima. 2016. Systemic Sclerosis. Systemic Sclerosis 103 115 .
Alejandro Souto, José Ramón Maneiro & Juan J. Gómez-Reino. (2015) Rate of discontinuation and drug survival of biologic therapies in rheumatoid arthritis: a systematic review and meta-analysis of drug registries and health care databases. Rheumatology, pages kev374.
Crossref
Alejandro Balsa, Juan Víctor Tovar Beltrán, Rafael Cáliz Cáliz, Isabel Mateo Bernardo, Rosario García-Vicuña, Manuel Rodríguez-Gómez, Miguel Angel Belmonte Serrano, Carlos Marras, Eduardo Loza Cortina, Eva Pérez-Pampin & Vicente Vila. (2015) Patterns of use and dosing of tocilizumab in the treatment of patients with rheumatoid arthritis in routine clinical practice: the ACT-LIFE study. Rheumatology International 35:9, pages 1525-1534.
Crossref
Atsushi Ogata, Takayoshi Morita, Yuji Yoshida & Toshio Tanaka. (2015) Subcutaneous formulation of tocilizumab for treatment of rheumatoid arthritis. Therapeutic Delivery 6:3, pages 283-295.
Crossref
Sofia Ramiro, Cécile Gaujoux-Viala, Jackie L Nam, Josef S Smolen, Maya Buch, Laure Gossec, Désirée van der Heijde, Kevin Winthrop & Robert Landewé. (2014) Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis. Annals of the Rheumatic Diseases 73:3, pages 529-535.
Crossref
Josef S Smolen, Robert Landewé, Ferdinand C Breedveld, Maya Buch, Gerd Burmester, Maxime Dougados, Paul Emery, Cécile Gaujoux-Viala, Laure Gossec, Jackie Nam, Sofia Ramiro, Kevin Winthrop, Maarten de Wit, Daniel Aletaha, Neil Betteridge, Johannes W J Bijlsma, Maarten Boers, Frank Buttgereit, Bernard Combe, Maurizio Cutolo, Nemanja Damjanov, Johanna M W Hazes, Marios Kouloumas, Tore K Kvien, Xavier Mariette, Karel Pavelka, Piet L C M van Riel, Andrea Rubbert-Roth, Marieke Scholte-Voshaar, David L Scott, Tuulikki Sokka-Isler, John B Wong & Désirée van der Heijde. (2014) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Annals of the Rheumatic Diseases 73:3, pages 492-509.
Crossref
Marc Cohen, Mohammed A Omair & Edward C Keystone. (2013) Monoclonal antibodies in rheumatoid arthritis. International Journal of Clinical Rheumatology 8:5, pages 541-556.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.